The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies.
| Title: | The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies. |
|---|---|
| Authors: | Annapragada A; Edward B. Singleton Department of Radiology, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA.; Sikora AG; Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Marathe H; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Liu S; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Demetriou M; Department of Neurology, University of California, Irvine, Irvine, CA, USA.; Department of Microbiology and Molecular Genetics, University of California, Irvine, Irvine, CA, USA.; Fong L; Department Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.; Parker Institute of Cancer Immunotherapy, San Francisco, CA, USA.; Gao J; Department of Pharmacology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Otolaryngology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Biomedical Engineering, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Kufe D; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Morris ZS; Department of Human Oncology, University of Wisconsin-Madison, Madison, WI, USA.; Vilar E; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Sharon E; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Hutson A; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Odunsi K; University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.; Department of Obstetrics and Gynecology, The University of Chicago, Chicago, IL, USA. |
| Source: | Journal of the National Cancer Institute [J Natl Cancer Inst] 2023 Nov 08; Vol. 115 (11), pp. 1262-1270. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Language: | English |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE |
| Imprint Name(s): | Publication: : Cary, NC : Oxford University Press; Original Publication: Bethesda, Md., U. S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health; Washington, for sale by the Supt. of Docs., U. S. Govt. Print. Off. |
| MeSH Terms: | Neoplasms*/therapy; Adult ; Humans ; Medical Oncology ; Immunotherapy |
| Abstract: | The Immuno-Oncology Translational Network (IOTN) was established in 2018 as part of the Cancer Moonshot. In 2022, President Joe Biden set new goals to reduce the cancer death rate by half within 25 years and improve the lives of people with cancer and cancer survivors. The IOTN is focused on accelerating translation of cancer immunology research, from bench to bedside, and improving immunotherapy outcomes across a wide array of cancers in the adult population. The unique structure and team science approach of the IOTN is designed to accelerate discovery and evaluation of novel immune-based therapeutic and prevention strategies. In this article, we describe IOTN progress to date, including new initiatives and the development of a robust set of resources to advance cancer immunology research. We summarize new insights by IOTN researchers, some of which are ripe for translation for several types of cancers. Looking to the future, we identify barriers to the translation of immuno-oncology concepts into clinical trials and key areas for action and improvements that are suitable for high-yield investments. Based on these experiences, we recommend novel National Institutes of Health funding mechanisms and development of new resources to address these barriers.; (© The Author(s) 2023. Published by Oxford University Press.) |
| References: | Nature. 2019 Mar;567(7749):530-534. (PMID: 30814732); Clin Cancer Res. 2020 Jul 1;26(13):3345-3359. (PMID: 32193227); Nature. 2020 Jul;583(7817):609-614. (PMID: 32581358); Sci Adv. 2020 Jul 10;6(28):eaba6156. (PMID: 32832602); Cancer Discov. 2023 May 4;13(5):1049-1052. (PMID: 37067233); Science. 2020 Aug 21;369(6506):942-949. (PMID: 32820120); Immunity. 2020 Jan 14;52(1):17-35. (PMID: 31940268); Gastroenterology. 2021 Oct;161(4):1288-1302.e13. (PMID: 34224739); J Immunother Cancer. 2020 Jun;8(1):. (PMID: 32554617); Adv Mater. 2019 Oct;31(43):e1902626. (PMID: 31523868); Nat Biomed Eng. 2021 May;5(5):455-466. (PMID: 33558734); Cancer Cell. 2022 May 9;40(5):545-557.e13. (PMID: 35427494); Nat Nanotechnol. 2021 Nov;16(11):1260-1270. (PMID: 34594005); Clin Cancer Res. 2019 Jul 15;25(14):4211-4223. (PMID: 30814108); J Immunother Cancer. 2019 Aug 13;7(1):216. (PMID: 31409394); J Immunother Cancer. 2022 Jan;10(1):. (PMID: 35058328); J Immunother Cancer. 2021 Oct;9(10):. (PMID: 34607898); Sci Transl Med. 2021 Jul 14;13(602):. (PMID: 34261797); Nat Commun. 2019 Mar 20;10(1):1280. (PMID: 30894532); Nat Biomed Eng. 2021 Nov;5(11):1261-1273. (PMID: 34725504); J Immunother Cancer. 2019 Jan 15;7(1):10. (PMID: 30646957); Science. 2021 Mar 12;371(6534):1166-1171. (PMID: 33632893); J Clin Invest. 2020 Apr 1;130(4):1635-1652. (PMID: 31874109); J Immunother Cancer. 2021 Jun;9(6):. (PMID: 34172518); Nat Commun. 2020 Nov 10;11(1):5696. (PMID: 33173046); Clin Cancer Res. 2019 Jul 15;25(14):4400-4412. (PMID: 31010834); Cancer Discov. 2023 May 4;13(5):1084-1099. (PMID: 37067240); Nature. 2022 Jul;607(7918):360-365. (PMID: 35676488); Sci Rep. 2019 Jan 23;9(1):358. (PMID: 30674975); Sci Data. 2016 Mar 15;3:160018. (PMID: 26978244); J Immunother Cancer. 2019 Jun 20;7(1):156. (PMID: 31221207); Nat Med. 2022 Jul;28(7):1345-1347. (PMID: 35760861); Nat Commun. 2021 Apr 22;12(1):2383. (PMID: 33888713); Gynecol Oncol. 2021 Jul;162(1):203-209. (PMID: 33722417); Clin Cancer Res. 2017 Sep 1;23(17):4959-4969. (PMID: 28864724); Sci Transl Med. 2021 Apr 28;13(591):. (PMID: 33910979); Nat Immunol. 2021 Aug;22(8):983-995. (PMID: 34282330); Cancer Res. 2020 Feb 15;80(4):732-746. (PMID: 31848196); Sci Adv. 2021 Oct 08;7(41):eabg5841. (PMID: 34613775) |
| Grant Information: | U01 CA233056 United States CA NCI NIH HHS; U24 CA232979 United States CA NCI NIH HHS; U01 CA233102 United States CA NCI NIH HHS; U01 CA233085 United States CA NCI NIH HHS; U01 CA233078 United States CA NCI NIH HHS; U54 CA244719 United States CA NCI NIH HHS; U01DE028233 United States NH NIH HHS; U01 CA233100 United States CA NCI NIH HHS; U01 CA244452 United States CA NCI NIH HHS; U01 CA233084 United States CA NCI NIH HHS |
| Entry Date(s): | Date Created: 20230812 Date Completed: 20231113 Latest Revision: 20250104 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10637038 |
| DOI: | 10.1093/jnci/djad151 |
| PMID: | 37572314 |
| Database: | MEDLINE |
Journal Article; Research Support, N.I.H., Extramural